ProQR Therapeutics N.V. (PRQR)
NASDAQ: PRQR · Real-Time Price · USD
1.590
-0.020 (-1.24%)
At close: May 12, 2025, 4:00 PM
1.590
0.00 (0.00%)
After-hours: May 12, 2025, 4:05 PM EDT
ProQR Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for ProQR Therapeutics stock have an average target of 9.00, with a low estimate of 4.00 and a high estimate of 14. The average target predicts an increase of 466.04% from the current stock price of 1.59.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ProQR Therapeutics stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 4 | 4 | 4 | 4 |
| Buy | 1 | 1 | 1 | 1 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Evercore ISI Group | Evercore ISI Group | Buy Initiates $5 | Buy | Initiates | $5 | +214.47% | Apr 29, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $4 | Strong Buy | Maintains | $4 | +151.57% | Mar 14, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $10 → $12 | Strong Buy | Maintains | $10 → $12 | +654.72% | Mar 14, 2025 |
| Jones Trading | Jones Trading | Strong Buy Initiates $11 | Strong Buy | Initiates | $11 | +591.82% | Feb 12, 2025 |
| JMP Securities | JMP Securities | Buy Reiterates $8 | Buy | Reiterates | $8 | +403.14% | Dec 12, 2024 |
Financial Forecast
Revenue This Year
20.80M
from 19.55M
Increased by 6.44%
Revenue Next Year
15.94M
from 20.80M
Decreased by -23.37%
EPS This Year
-0.41
from -0.32
EPS Next Year
-0.51
from -0.41
Financial currency is EUR. Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 44.7M | 21.0M | 20.1M | ||
| Avg | 20.8M | 15.9M | 6.6M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 128.7% | 0.9% | 26.2% | ||
| Avg | 6.4% | -23.4% | -58.8% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -0.18 | -0.39 | -0.35 |
| Avg | -0.41 | -0.51 | -0.53 |
| Low | -0.60 | -0.68 | -0.68 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.